Apr 23 |
Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
|
Apr 22 |
Artelo Biosciences CEO to Appear on Benzinga All Access on April 23rd at Approximately 10:50 AM Eastern Time
|
Mar 25 |
Recap: Artelo Biosciences Q4 Earnings
|
Mar 25 |
Artelo Biosciences GAAP EPS of -$3.14 misses by $0.58
|
Mar 25 |
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
|
Mar 12 |
Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge
|
Feb 15 |
Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th
|
Jan 23 |
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12’s Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
|
Jan 8 |
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
|
Dec 5 |
Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
|